质子抑制剂的使用和患者的缺铁性贫血
Stephanie Hawkins1, Meghali Nighot2, Shannon Dalessio3
1Penn State College of Medicine, Hershey, Pennsylvania, USA.
Digestive diseases (Basel, Switzerland)
|November 8, 2023
概括
质子抑制剂 (PPI) 的使用与乳病患者的缺铁性贫血 (IDA) 有显著的关联. 考虑IPI的替代品,以治疗IDA的乳患者.
科学领域:
- 胃肠病学 胃肠病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 病 (CD) 是一种影响小肠的自身免疫性疾病.
- 缺铁性贫血 (IDA) 是乳病患者的常见并发症.
- 质子抑制剂 (PPI) 是经常用于抑制酸性的药物.
研究的目的:
- 评估使用质子抑制剂 (PPI) 与患有乳病 (CD) 患者的缺铁性贫血 (IDA) 的发展和严重程度之间的关联.
主要方法:
- 对成年患有乳病的患者进行了回顾性图表审查.
- 基于IDA诊断和PPI使用的四个队列的分析.
- 根据贫血严重程度对患有IDA的乳患者的分层.
主要成果:
- 在366名乳患者中,25.1%的患者被诊断为IDA.
- 65.2%的IDA乳患者使用PPI.
- 与那些没有PPI (12.1 g/dL,p=0.04) 相比,在PPI (11.1 g/dL) 上使用IDA的乳患者中,血红蛋白的平均水平较低.
结论:
- 在乳病患者的PPI使用和IDA之间存在显著的关联 (p < 0.0001).
- 患有IDA的乳患者的贫血严重程度根据PPI使用情况没有显著差异.
- 停止治疗或替代性抑制酸的治疗可能是有必要的对于患有IDA的乳患者.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
438
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438
Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Peptic Ulcer Disease I: Introduction
179
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
179
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
438
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
438
Factors Influencing Drug Absorption: Disease States and Pharmacology
535
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
535


